Key Insights

Highlights

Success Rate

91% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

2.0%

1 terminated out of 50 trials

Success Rate

90.9%

+4.4% vs benchmark

Late-Stage Pipeline

2%

1 trials in Phase 3/4

Results Transparency

0%

0 of 10 completed with results

Key Signals

91% success

Data Visualizations

Phase Distribution

42Total
Not Applicable (8)
Early P 1 (2)
P 1 (30)
P 2 (1)
P 3 (1)

Trial Status

Recruiting23
Completed10
Not Yet Recruiting8
Withdrawn4
Unknown2
Enrolling By Invitation1

Trial Success Rate

90.9%

Benchmark: 86.5%

Based on 10 completed trials

Clinical Trials (50)

Showing 20 of 20 trials
NCT05520099Active Not Recruiting

Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform

NCT07052760Early Phase 1WithdrawnPrimary

Imaging of Solid Tumors Using DLL3 SPECT

NCT07193511Phase 1RecruitingPrimary

BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)

NCT06607692Phase 1RecruitingPrimary

Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

NCT06682117Not ApplicableRecruiting

A Clinical Study of Personalized Self-DC Vaccine Targeting Neoantigen in Treatment of Advanced Solid Tumor

NCT07424547Phase 1Recruiting

Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors

NCT07492173Not ApplicableCompletedPrimary

Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans

NCT06108479Phase 1Completed

Study of DF6215 in Patients With Advanced Solid Tumors

NCT07467629Phase 1Not Yet RecruitingPrimary

QLS5212 for Participants With Advanced Solid Tumors

NCT06802172Not ApplicableRecruiting

Effect of Meal Timing During Cancer Treatment in Patients in Alaska: A Randomized Clinical Trial

NCT07441174Phase 1RecruitingPrimary

IN10018 in Combination With RNK08954 for the Treatment of KRASG12D Mutation-Positive Locally Advanced or Metastatic Solid Tumors

NCT04354064Recruiting

Circulating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors

NCT07038343Phase 1RecruitingPrimary

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

NCT07337525Phase 1Recruiting

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

NCT07218874Not ApplicableRecruiting

Feasibility and Acceptability of the Remote Oncology Symptom Assessment Application

NCT06922825Early Phase 1WithdrawnPrimary

Pilot Study Evaluating Tumor Microenvironment Interaction in Solid Tumor Patients

NCT06846099Phase 1Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Efficacy and Indications of RP903

NCT07268066RecruitingPrimary

Implementation of the Methylome in the Characterization of Solid Tumors

NCT07269899Phase 1RecruitingPrimary

A Phase I Study of WTX212A Monotherapy or in Combination With Radiotherapy in Patients With Advanced Solid Tumors

NCT07264803Phase 2Recruiting

A Single-arm Clinical Trial Using Patient-derived Tumor Tissue Fragment Models for Drug Sensitivity Testing to Guide Treatment in Previously Treated Cancers

Scroll to load more

Research Network

Activity Timeline